38.0% Clinical pregnancy rate per embryo transferred in CY22 (women aged <43 years) compared to 32.6% in CY18; this increased to 38.7% in Q1 CY23;
Further progress in South-East Asia growth strategy.
Not much on ESG here vs what the big 4 banks have to be grilled on.lol
Have the scientist studied the environmental impact of the industry?
Return (inc div) 1yr: 33.16% 3yr: 25.71% pa 5yr: 11.10% pa
Monash IVF Group spent $12.7m on business acquisitions in FY23. The ART Associates QLD acquisition was completed in late September 2023, delivering strong market share gains in Queensland in FY23. The PIVET acquisition was completed in late May 2023 with clinics in Perth and Cairns, resulting in Monash IVF Group having true national mainland presence.
Despite the major investments we have made in future growth across our businesses in recent years, our balance sheet remains in a strong position. Net debt was $31.0m as at 30 June 2023 and balance sheet capacity remains strong to fund domestic and South East Asia market growth where Monash IVF Group is under-represented. In closing,
I would like to thank our People and Clinicians for their hard work and dedication, and to thank you, our shareholders, for your continuing support.
We are energised about the journey ahead for Monash IVF Group, as we move closer to achieving our strategic objectives. Malik Jainudeen Chief Financial Officer & Company Secretary
Almost a 52 week
Return (inc div) 1yr: 48.13% 3yr: 37.89% pa 5yr: 14.00% pa
